Compare Dow Inc (DOW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Dow Inc trades at $30.59 (market cap $22.58B), while State Street SPDR S&P Biotech ETF trades at $159.14. The key difference: Dow Inc pays a 4.48% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Dow Inc nearer its low. Which is the better fit depends on your goals.
| DOW | XBI | |
|---|---|---|
Market Cap | $22.58B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $41.87 | $164.28 |
52-Week Low | $20.65 | $86.92 |
Enterprise Value | $38.27B | — |
Dividend Yield | 4.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.78, up 0.65% today, with a bullish technical signal and positive earnings beats in recent quarters. However, the company reported a net loss of $2.62 billion in 2025, with declining revenue and negative profit margins. Analyst consensus is a 'Hold' with a $35.11 price target, suggesting modest upside potential from current levels.
The outlook is mixed; earnings improvements and dividend payments provide support, but persistent losses and high debt pose risks. Investment opportunity hinges on a turnaround in profitability, while key risks include competitive pressures and macroeconomic headwinds affecting the chemicals sector.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
